Everence Capital Management Inc Vertex Pharmaceuticals Inc Transaction History

Everence Capital Management Inc

$1.59 Billion
Q3 2024

A detailed history of Everence Capital Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Everence Capital Management Inc holds 5,344 shares of VRTX stock, worth $2.48 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

5,344

Previous 5,344 -0.0%

Holding current value

$2.48 Million

Previous $2.1 Million 18.39%

% of portfolio

0.16%

Previous 0.15%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	SELL	$343.0 - $410.68 $1.02 Million - $1.22 Million	-2,980 Reduced 35.8%	5,344 $2.17 Million
Q1 2023 Apr 04, 2023	SELL	$283.23 - $323.1 $705,242 - $804,519	-2,490 Reduced 23.03%	8,324 $2.62 Million
Q4 2022 Jan 31, 2023	BUY	$285.76 - $321.48 $1.15 Million - $1.3 Million	4,030 Added 59.4%	10,814 $3.12 Million
Q2 2022 Jul 26, 2022	BUY	$234.96 - $292.55 $253,756 - $315,954	1,080 Added 18.93%	6,784 $1.91 Million
Q1 2022 Apr 11, 2022	SELL	$221.42 - $260.97 $347,629 - $409,722	-1,570 Reduced 21.58%	5,704 $1.49 Million
Q3 2021 Oct 21, 2021	BUY	$181.39 - $202.99 $284,782 - $318,694	1,570 Added 27.52%	7,274 $1.32 Million
Q3 2020 Feb 01, 2021	SELL	$255.65 - $303.1 $46,017 - $54,558	-180 Reduced 3.06%	5,704 $1.55 Million
Q4 2017 Feb 02, 2018	SELL	$137.28 - $155.55 $154,851 - $175,460	-1,128 Reduced 16.09%	5,884 $882,000
Q3 2017 Oct 31, 2017	BUY	$148.13 - $162.24 $1.04 Million - $1.14 Million	7,012	7,012 $1.07 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Everence Capital Management Inc with notifications on news.

Account

Everence Capital Management Inc Vertex Pharmaceuticals Inc Transaction History